Compare FSK & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSK | BLLN |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | N/A | 2025 |
| Metric | FSK | BLLN |
|---|---|---|
| Price | $14.49 | $99.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $17.33 | ★ $137.83 |
| AVG Volume (30 Days) | ★ 2.8M | 210.6K |
| Earning Date | 02-25-2026 | 12-09-2025 |
| Dividend Yield | ★ 19.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $1,578,000,000.00 | $254,136,000.00 |
| Revenue This Year | N/A | $97.80 |
| Revenue Next Year | N/A | $35.87 |
| P/E Ratio | $15.00 | ★ N/A |
| Revenue Growth | N/A | ★ 254.30 |
| 52 Week Low | $14.05 | $80.51 |
| 52 Week High | $24.10 | $138.70 |
| Indicator | FSK | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | N/A |
| Support Level | $14.12 | N/A |
| Resistance Level | $14.81 | N/A |
| Average True Range (ATR) | 0.28 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 35.57 | 0.00 |
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.